National Technical Reports Library

The National Technical Information Service acquires, indexes, abstracts, and archives the largest collection of U.S. government-sponsored technical reports in existence. The NTRL offers online, free and open access to these authenticated government technical reports. Technical reports and documents in its repository may be available online for free either from the issuing federal agency, the U.S. Government Publishing Office’s Federal Digital System website, or through search engines.

Details

DE2005833647

Publication Date	2004
Page Count	14
Abstract	The successful clinical application of targeted-radiopharmaceuticals depends on the development of molecules that optimize tumor specific radionuclide deposition and minimize non-specific organ irradiation. To this end, this proposal outlines a research effort to identify and evaluate novel antibodies and antibody fragments that bind breast tumors. The tumor-avid antibodies will be investigated for as imaging and therapeutic agents and to gain a better understanding of the pharmacokinetics and metabolism of radiolabeled tumor-avid antibody fragments through the use of site-specifically labeled molecules. Antibodies or antibody fragments, that bind breast carcinoma carbohydrate antigens, will be obtained from hybridoma or bacteriophage library screening.
Keywords	Radionuclide chelation Amino acids Antibodies Antigens Bacteriophages Carcinomas Drugs Hybridomas In vivo Irradiation Mammary glands Metabolism Neoplasms Organs Radioisotopes Nuclear medicine Tumor specific radionuclide deposition Targeted-radiopharmaceuticals
Source Agency	Technical Information Center Oak Ridge Tennessee
Corporate Authors	Department of Energy, Chicago, IL. Chicago Operations Office.
Document Type	Technical Report
NTIS Issue Number	200519

Characterization of Tumor-Avid Antibody Fragments Genetically Engineered for Mono-Specific Radionuclide Chelation.

Characterization of Tumor-Avid Antibody Fragments Genetically Engineered for Mono-Specific Radionuclide Chelation.
DE2005833647

Publication Date	2004
Page Count	14
Abstract	The successful clinical application of targeted-radiopharmaceuticals depends on the development of molecules that optimize tumor specific radionuclide deposition and minimize non-specific organ irradiation. To this end, this proposal outlines a research effort to identify and evaluate novel antibodies and antibody fragments that bind breast tumors. The tumor-avid antibodies will be investigated for as imaging and therapeutic agents and to gain a better understanding of the pharmacokinetics and metabolism of radiolabeled tumor-avid antibody fragments through the use of site-specifically labeled molecules. Antibodies or antibody fragments, that bind breast carcinoma carbohydrate antigens, will be obtained from hybridoma or bacteriophage library screening.
Keywords	Radionuclide chelation Amino acids Antibodies Antigens Bacteriophages Carcinomas Drugs Hybridomas In vivo Irradiation Mammary glands Metabolism Neoplasms Organs Radioisotopes Nuclear medicine Tumor specific radionuclide deposition Targeted-radiopharmaceuticals
Source Agency	Technical Information Center Oak Ridge Tennessee
Corporate Authors	Department of Energy, Chicago, IL. Chicago Operations Office.
Document Type	Technical Report
NTIS Issue Number	200519